Filing Details

Accession Number:
0000950170-24-010967
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-02-02 21:24:58
Reporting Period:
2024-01-31
Accepted Time:
2024-02-02 21:24:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1593899 Atea Pharmaceuticals Inc. AVIR Pharmaceutical Preparations (2834) 460574869
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1829899 Mj Janet Hammond 225 Franklin Street
Suite 2100
Boston MA 02110
Chief Development Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-01-31 46,800 $0.00 49,391 No 4 M Direct
Common Stock Disposition 2024-02-01 14,029 $3.84 35,362 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2024-01-31 46,800 $0.00 46,800 $0.00
Common Stock Stock Option (Right to Buy) Acquisiton 2024-01-31 225,200 $0.00 225,200 $4.16
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
93,600 No 4 M Direct
225,200 2034-01-30 No 4 A Direct
Footnotes
  1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
  2. Includes 2,591 additional shares acquired under the Atea Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan.
  3. Shares were sold solely to cover taxes upon the vesting of restricted stock units pursuant to a standing Rule 10b5-1 instruction dated March 14, 2022.
  4. The original grant of 140,400 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026.
  5. The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2024 such that the option is fully vested on January 31, 2028.